期刊
JOURNAL OF HEPATOLOGY
卷 63, 期 3, 页码 722-732出版社
ELSEVIER
DOI: 10.1016/j.jhep.2015.05.019
关键词
Hepatocellular carcinoma; Hepatitis B virus; Cirrhosis; Transient elastography; HBV DNA
资金
- Abbott
- Anadys
- Bristol-Myers Squibb
- Gilead Sciences
- Innogenetics
- Medtronic
- Merck
- Novartis
- Roche
- Santaris
- Tibotec
Chronic hepatitis B is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Accurate prediction of HCC risk is important for decisions on antiviral therapy and HCC surveillance. In the last few years, a number of Asian groups have derived and validated several HCC risk scores based on well-known risk factors such as cirrhosis, age, male sex and high viral load. Overall, these scores have high negative predictive values of over 95% in excluding HCC development in 3 to 10 years. The REACH-B score was derived from a community cohort of non-cirrhotic patients and is better applied in the primary care setting. In contrast, the GAG-HCC and CU-HCC scores were derived from hospital cohorts and include cirrhosis as a major integral component. While the latter scores may be more applicable to patients at specialist clinics, the diagnosis of cirrhosis based on routine imaging and clinical parameters can be inaccurate. To this end, recent developments in non-invasive tests of liver fibrosis may further refine the risk prediction. The application of HCC risk scores in patients on antiviral therapy and in other ethnic groups should be evaluated in future studies. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据